Fintepla 2.2 mg/ml, solution buvable

7680693710016 CH-69371 Lösung
Fintepla 2.2 mg/ml, solution buvable
Fintepla 2.2 mg/ml, solution buvable
Fintepla 2.2 mg/ml, solution buvable
1 / 3
google

Article details

Package size
120 ml
Selling units
120
Measure
Flasche(n)
Galenic form
Lösung
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
17/10/2025
Patient information leaflet
Français
17/10/2025
Patient information leaflet
Italien
17/10/2025
Summary of Product Characteristics
Allemand
17/10/2025
Summary of Product Characteristics
Français
17/10/2025
Summary of Product Characteristics
Italien
17/10/2025

Detailed composition

Substance Quantity Type Category
(N/A)
2.2 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
2.3 MG Substance HBESI
(N/A)
0.23 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance AROMA
(N/A)
- Substance HBESI
(N/A)
- Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
0.33 MG Substance HBESI

Authorization holder

UCB-Pharma SA

1630 Bulle

Authorization information

Swissmedic authorization number
69371
Drug name
Fintepla, solution buvable
Galenic form
LSOR
ATC Code
N03AX26
Authorization status
Z
Dispensing category
A
First authorization
13/02/2025
Authorization expiration date
12/02/2030
IT Number
01.07.1.
Domain
Human medicine
Field of application
Zusatztherapie bei Krampfanfällen in Zusammenhang mit dem Dravet-Syndrom (DS) oder dem Lennox-Gastaut-Syndrom (LGS), bei Patienten ab 2 Jahren

Package details

Description (FR)
FINTEPLA sol 2.2 mg/ml buvable fl 120 ml
Description (DE)
FINTEPLA Lös 2.2 mg/ml zum Einnehmen Fl 120 ml
Market launch
13/02/2025
Narcotic (BTM)
No

Other package sizes (1)

FINTEPLA sol 2.2 mg/ml buvable fl 360 ml
360 ml FLAS
GTIN: 7680693710023
View